-
Variability in Health Utility Scores in Pancreatic Cancer: Findings From a Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Cost Comparison of Alternative Delivery Routes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) in the English National Health Service (NHS)
Sep 9, 2025, 16:22 PM -
Global Economic Burden of Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Literature Review
Sep 9, 2025, 16:22 PM -
Fitting Flexible Survival Models to Landmark Survival Estimates in R
Sep 9, 2025, 16:22 PM -
Comparing Robotic-Assisted Coronary Artery Bypass Grafting Using the Da Vinci Surgical System to a Nonrobotic Approach: A Systematic Literature Review and Meta-Analysis
Sep 9, 2025, 16:22 PM -
Evolution of High-Efficacy Therapies for Relapsing Multiple Sclerosis: Does Innovation Meet Patient Preferences?
Sep 9, 2025, 16:22 PM -
Barriers to Reimbursement: Characteristics of Unfunded Medicines in Ireland (2006-2021)
Sep 9, 2025, 16:22 PM -
The Perils of Treatment Crossover in Clinical Trials
Sep 9, 2025, 16:22 PM -
Health Utility Values in Adults With Primary Biliary Cholangitis: A Global Systematic Literature Review
Sep 9, 2025, 16:22 PM -
The Next Steps Matter? New Cancer Medicines and Their Indication Extensions in Europe 2010-2020
Sep 9, 2025, 16:22 PM -
Leveraging Large-Language Models for Medical Code List Creation: An Example Using the Charlson Comorbidity Index
Sep 9, 2025, 16:22 PM -
Medical Resource Utilizations and Economic Burden of Chemotherapy-Induced Anemia in Chinese Population: A Multicenter Retrospective Study
Sep 9, 2025, 16:22 PM -
Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond
Sep 9, 2025, 16:22 PM -
International Reference Pricing (IRP) Analysis for Generic Medicines in Türkiye in 2024
Sep 9, 2025, 16:22 PM -
Stakeholder Involvement in the Health Technology Assessment Process in Ukraine
Sep 9, 2025, 16:22 PM -
What Is the Cost of Preventing Tuberculosis a Cost-Effectiveness Analysis of Household Contact Tracing With 3HP Preventive Therapy in High-Burden Areas of Nepal?
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis of Introducing Nirsevimab Into the National Immunization Program for Infants in Korea
Sep 9, 2025, 16:22 PM -
Quantifying the Opportunity Costs of Intra-Direct Oral Anticoagulants (DOAC) Switching Pathways Across the National Health Service (NHS) in England: A Structured Framework
Sep 9, 2025, 16:22 PM -
Recent Changes in HTA and Reimbursement Requirements: Learnings for Global Dossiers
Sep 9, 2025, 16:22 PM -
Let LAMBA Do the Work: Can We Reduce Reliance on VBA in Health Economic Models?
Sep 9, 2025, 16:22 PM
